ECE2017 Eposter Presentations: Adrenal and Neuroendocrine Tumours Adrenal cortex (to include Cushing's) (86 abstracts)
Effect of GH treatment on coagulation and fibrinolysis parameters in prepubertal children with growth hormone deficiency
Feneli Karachaliou 1 , Maria Kafetzi 2 , Maria Drakopoulou 3 , Elpis Vlachopapadopoulou 4 , Sofia Leka-Emiris 4 , Aspasia Fotinou 2 & Stefanos Michalakos 4
1Pediatric Endocrinology Unit, 3rd Department of Pediatrics, University General Hospital Attikon, Athens, Greece; 2Biochemistry-Hormonology Department, P & A Kyriakou Children’s Hospital, Athens, Greece; 3Endocrine Unit, Choremis Research Laboratory, A Pediatric Department, Athens University Medical School, Aghia Sophia Children’s Hospital, Athens, Greece; 4Endocrinology Department, ‘P. & A. Kyriakou’ Children’s Hospital, Athens, Greece.
Background: Increased fibrinogen levels have been reported in prepubertal children and adolescents with growth hormone deficiency (GHD), which were reduced after rhGH treatment. rhGH treatment has also been shown to exert a beneficial effect on the amount of aPAI-1 in children with GHD.
Aim: Of the study was to evaluate whether prepubertal GH deficient (GHD) children showed any impairment in coagulation- and fibrinolysis-related parameters and the effect of GH therapy on these parameters.
Patients and methods: Fifteen prepubertal children (10 girls and five boys) of a mean (S.D.) age of 9.8 (0.4) years with GH deficiency were included in this hospital based prospective study. Serum levels of PT, APTT, fibrinogen, VII, VIII, AT, PC, D-dimers, Plg, and PAI-1 were measured before and after 6–12 months of GH treatment.
Results: At baseline all studied parameters were within normal ranges. A significant increase in PT values was noted after a mean (S.D.) interval of 9.3 (0.4) months of treatment: 12.46 (0.2) s vs 12.1(0.15) s, P=0.045. A significant decrease in PAI-1 levels (3.04 (0.1) U/ml vs 2.28 (0.3) U/ml, P=0.018) was noted at the same time. No significant changes in the rest of parameters were found during the study period.
Conclusion: GH replacement therapy for 6–12 months led to a significant increase in PT values, while fibrinogen levels did not change. Moreover, GH treatment reduced PAI-1 levels in GHD children, suggesting a beneficial effect of GH treatment on possible risk of future atherothrombosis. Further evaluation of the clinical significance of these changes is needed.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more